$MASI
MASIMO CORP

2021 Q4 Form 10-Q Financial Statement

#000093755621000124 Filed on October 26, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q1 2020 Q3
Revenue $307.4M $295.1M $278.1M
YoY Change 9.45% 21.44%
Cost Of Revenue $103.8M $108.1M $99.19M
YoY Change 28.7% 36.35%
Gross Profit $203.7M $186.9M $178.9M
YoY Change 0.68% 14.5%
Gross Profit Margin 66.25% 63.33% 64.34%
Selling, General & Admin $100.6M $90.30M $90.38M
YoY Change 0.47% 12.47%
% of Gross Profit 49.42% 48.31% 50.51%
Research & Development $35.41M $31.70M $28.85M
YoY Change 16.37% 18.82%
% of Gross Profit 17.38% 16.96% 16.13%
Depreciation & Amortization $6.500M $8.100M $5.800M
YoY Change 26.98% 20.83%
% of Gross Profit 3.19% 4.33% 3.24%
Operating Expenses $136.1M $122.1M $119.2M
YoY Change 4.7% 13.95%
Operating Profit $67.61M $64.80M $59.70M
YoY Change -6.1% 15.62%
Interest Expense $87.00K $1.700M $84.00K
YoY Change 1923.81% 2.44%
% of Operating Profit 0.13% 2.62% 0.14%
Other Income/Expense, Net -$78.00K $100.0K $1.357M
YoY Change -97.01% -50.17%
Pretax Income $67.53M $66.70M $61.06M
YoY Change -7.82% 12.33%
Income Tax $9.762M -$3.900M $11.65M
% Of Pretax Income 14.46% -5.85% 19.08%
Net Earnings $57.77M $70.70M $49.41M
YoY Change 9.69% 0.65%
Net Earnings / Revenue 18.79% 23.96% 17.76%
Basic Earnings Per Share $1.05 $0.90
Diluted Earnings Per Share $1.00 $1.219M $0.85
COMMON SHARES
Basic Shares Outstanding 55.14M shares 55.27M shares 55.00M shares
Diluted Shares Outstanding 57.66M shares 58.28M shares

Balance Sheet

Concept 2021 Q4 2021 Q1 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $652.4M $641.4M $719.1M
YoY Change -2.21% 13.53%
Cash & Equivalents $652.4M $641.4M $669.1M
Short-Term Investments $0.00 $50.00M
Other Short-Term Assets $91.77M $102.4M $88.27M
YoY Change 84.83% 45.26%
Inventory $202.3M $216.0M $204.8M
Prepaid Expenses $30.35M $30.24M $29.47M
Receivables $191.3M $141.4M $146.9M
Other Receivables $38.76M $40.00M $34.20M
Total Short-Term Assets $1.138B $1.101B $1.159B
YoY Change 12.35% 24.06%
LONG-TERM ASSETS
Property, Plant & Equipment $274.9M $272.5M $267.2M
YoY Change 7.65% 27.55%
Goodwill $101.2M $103.2M $80.22M
YoY Change 90.78% 264.69%
Intangibles $74.09M $73.92M $57.31M
YoY Change 58.16% 108.9%
Long-Term Investments $13.93M $8.002M $7.950M
YoY Change 26.98% 26.45%
Other Assets $49.89M $44.64M $38.55M
YoY Change 25.49% 31.2%
Total Long-Term Assets $629.0M $611.4M $554.2M
YoY Change 23.67% 45.84%
TOTAL ASSETS
Total Short-Term Assets $1.138B $1.101B $1.159B
Total Long-Term Assets $629.0M $611.4M $554.2M
Total Assets $1.767B $1.713B $1.713B
YoY Change 16.14% 30.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $60.71M $64.06M $89.53M
YoY Change 30.44% 119.6%
Accrued Expenses $12.05M $6.794M $6.545M
YoY Change 24.52% 21.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $228.3M $233.8M $232.8M
YoY Change 48.66% 55.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.511M $71.08M $3.950M
YoY Change 2527.58% 79.22%
Total Long-Term Liabilities $4.511M $71.08M $3.950M
YoY Change 2527.58% 79.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $228.3M $233.8M $232.8M
Total Long-Term Liabilities $4.511M $71.08M $3.950M
Total Liabilities $298.6M $304.9M $298.3M
YoY Change 37.8% 44.93%
SHAREHOLDERS EQUITY
Retained Earnings $1.503B $1.341B $1.271B
YoY Change 15.09% 21.29%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $767.7M $638.7M $527.2M
YoY Change 21.21% 1.98%
Treasury Stock Shares 16.54M shares 15.99M shares 15.53M shares
Shareholders Equity $1.468B $1.408B $1.415B
YoY Change
Total Liabilities & Shareholders Equity $1.767B $1.713B $1.713B
YoY Change 16.14% 30.36%

Cashflow Statement

Concept 2021 Q4 2021 Q1 2020 Q3
OPERATING ACTIVITIES
Net Income $57.77M $70.70M $49.41M
YoY Change 9.69% 0.65%
Depreciation, Depletion And Amortization $6.500M $8.100M $5.800M
YoY Change 26.98% 20.83%
Cash From Operating Activities $81.89M $64.50M $40.40M
YoY Change 52.28% -20.16%
INVESTING ACTIVITIES
Capital Expenditures -$11.65M -$14.20M -$10.20M
YoY Change -138.37% 5.15%
Acquisitions
YoY Change
Other Investing Activities -$2.600M $12.30M $0.00
YoY Change -46.05% -100.0%
Cash From Investing Activities -$14.25M -$2.000M -$10.20M
YoY Change -87.0% -122.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.838M -93.30M 6.400M
YoY Change -929.41% -34.69%
NET CHANGE
Cash From Operating Activities 81.89M 64.50M 40.40M
Cash From Investing Activities -14.25M -2.000M -10.20M
Cash From Financing Activities 9.838M -93.30M 6.400M
Net Change In Cash 77.49M -30.80M 36.60M
YoY Change -180.59% -65.31%
FREE CASH FLOW
Cash From Operating Activities $81.89M $64.50M $40.40M
Capital Expenditures -$11.65M -$14.20M -$10.20M
Free Cash Flow $93.54M $78.70M $50.60M
YoY Change 1370.75% -16.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0000937556
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--01-01
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-10-02
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33642
dei Entity Registrant Name
EntityRegistrantName
MASIMO CORP
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0368882
dei Entity Address Address Line1
EntityAddressAddressLine1
52 Discovery
dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine,
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92618
dei City Area Code
CityAreaCode
(949)
dei Local Phone Number
LocalPhoneNumber
297-7000
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
MASI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55221689 shares
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
652354000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
641447000 USD
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2081000 USD
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1603000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
191332000 USD
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
141350000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
202328000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
215952000 USD
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
91772000 USD
CY2021Q1 us-gaap Other Assets Current
OtherAssetsCurrent
102416000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1137786000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
1101165000 USD
CY2021Q4 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
66955000 USD
CY2021Q1 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
57666000 USD
CY2021Q4 us-gaap Deferred Costs
DeferredCosts
22599000 USD
CY2021Q1 us-gaap Deferred Costs
DeferredCosts
20076000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
274929000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
272511000 USD
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
74089000 USD
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
73923000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
101242000 USD
CY2021Q1 us-gaap Goodwill
Goodwill
103206000 USD
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
39294000 USD
CY2021Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
39363000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
49886000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
44642000 USD
CY2021Q4 us-gaap Assets
Assets
1766780000 USD
CY2021Q1 us-gaap Assets
Assets
1712552000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
60710000 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
64061000 USD
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
69785000 USD
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
71601000 USD
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
46641000 USD
CY2021Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
44935000 USD
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
51118000 USD
CY2021Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
53239000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
228254000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
233836000 USD
CY2021Q4 us-gaap Deferred Credits And Other Liabilities
DeferredCreditsAndOtherLiabilities
70377000 USD
CY2021Q1 us-gaap Deferred Credits And Other Liabilities
DeferredCreditsAndOtherLiabilities
71076000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
298631000 USD
CY2021Q1 us-gaap Liabilities
Liabilities
304912000 USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1.000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1.000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2021Q1 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1.000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1.000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55222000 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55251000 shares
CY2021Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
55000 USD
CY2021Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
55000 USD
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
16540000 shares
CY2021Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
15993000 shares
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
767653000 USD
CY2021Q1 us-gaap Treasury Stock Value
TreasuryStockValue
638736000 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
736575000 USD
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
703693000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-3432000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
1413000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1502604000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1341215000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1468149000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1407640000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1766780000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1712552000 USD
CY2021Q4 us-gaap Revenues
Revenues
307414000 USD
CY2020Q3 us-gaap Revenues
Revenues
278112000 USD
us-gaap Revenues
Revenues
911575000 USD
us-gaap Revenues
Revenues
848690000 USD
CY2021Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
103750000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
99186000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
318124000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
292551000 USD
CY2021Q4 us-gaap Gross Profit
GrossProfit
203664000 USD
CY2020Q3 us-gaap Gross Profit
GrossProfit
178926000 USD
us-gaap Gross Profit
GrossProfit
593451000 USD
us-gaap Gross Profit
GrossProfit
556139000 USD
CY2021Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
100647000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
90376000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
291180000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
278714000 USD
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35406000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28852000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
103860000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86971000 USD
CY2021Q4 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
CY2020Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
474000 USD
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
136053000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
119228000 USD
us-gaap Operating Expenses
OperatingExpenses
395040000 USD
us-gaap Operating Expenses
OperatingExpenses
365211000 USD
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
67611000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
59698000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
198411000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
190928000 USD
CY2021Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-78000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1357000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-735000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6108000 USD
CY2021Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
67533000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
61055000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
197676000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
197036000 USD
CY2021Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9762000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11650000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
36287000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
27403000 USD
CY2021Q4 us-gaap Profit Loss
ProfitLoss
57771000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
49405000 USD
us-gaap Profit Loss
ProfitLoss
161389000 USD
us-gaap Profit Loss
ProfitLoss
169633000 USD
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.05
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.90
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.11
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.00
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.92
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55143000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54997000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55125000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54543000 shares
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57664000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58280000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57651000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58033000 shares
CY2021Q4 us-gaap Profit Loss
ProfitLoss
57771000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
49405000 USD
us-gaap Profit Loss
ProfitLoss
161389000 USD
us-gaap Profit Loss
ProfitLoss
169633000 USD
CY2021Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3165000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2653000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4845000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1504000 USD
CY2021Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
54606000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
52058000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
156544000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
171137000 USD
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1407640000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2886000 USD
CY2021Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
16691000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12708000 USD
CY2021Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
128917000 USD
CY2021Q2 us-gaap Profit Loss
ProfitLoss
53383000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2884000 USD
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1328125000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3442000 USD
CY2021Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
33000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8262000 USD
CY2021Q3 us-gaap Profit Loss
ProfitLoss
50235000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1204000 USD
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1391235000 USD
CY2021Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9748000 USD
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12560000 USD
CY2021Q4 us-gaap Profit Loss
ProfitLoss
57771000 USD
CY2021Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3165000 USD
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1468149000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1167874000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13495000 USD
CY2020Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1424000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11272000 USD
CY2020Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
371000 USD
CY2020Q1 us-gaap Income Tax Effects Allocated Directly To Equity Cumulative Effect Of Change In Accounting Principle
IncomeTaxEffectsAllocatedDirectlyToEquityCumulativeEffectOfChangeInAccountingPrinciple
439000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
64456000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2463000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1253278000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21213000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13188000 USD
CY2020Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
220000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
55772000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1314000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1344545000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6314000 USD
CY2020Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
25000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11912000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
49405000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2653000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1414804000 USD
us-gaap Profit Loss
ProfitLoss
161389000 USD
us-gaap Profit Loss
ProfitLoss
169633000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26449000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21200000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
33530000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
36372000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-371000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-202000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
647000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
5000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
136000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
50967000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9459000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-12329000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
86815000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-4433000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
23461000 USD
us-gaap Proceeds From Lease Payments
ProceedsFromLeasePayments
-9312000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
775000 USD
us-gaap Proceeds From Lease Payments
ProceedsFromLeasePayments
-6279000 USD
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
2573000 USD
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
1964000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
144000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4290000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
31793000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1298000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
3654000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3969000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4691000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-1456000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-2756000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1378000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
9973000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
634000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
395000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
167151000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
146545000 USD
us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
0 USD
us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
-70000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20680000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
60017000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
8185000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
5763000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
78310000 USD
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
2600000 USD
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
6750000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31465000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-80840000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
18975000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
40994000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
16724000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1449000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
128917000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
200000 shares
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
591000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-126666000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
38954000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-89000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-294000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8931000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
104365000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
645004000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
568075000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
653935000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
672440000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. Description of the Company </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Masimo Corporation (the Company) is a global medical technology company that develops, manufactures and markets a variety of noninvasive patient monitoring technologies, hospital automation solutions, home monitoring devices and consumer products. The Company’s mission is to improve patient outcomes, reduce the cost of care and take noninvasive monitoring to new sites and applications. The Company’s patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. The Company primarily sells its products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities, and consumers through its direct sales force, distributors and original equipment manufacturer (OEM) partners.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Masimo’s core measurement technologies are based on Measure-through Motion and Low Perfusion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pulse oximetry, known as Masimo Signal Extraction Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (SET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) pulse oximetry, and advanced rainbow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography, nasal high-flow respiratory support therapy, patient position and activity tracking and neuromodulation technology for the reduction of symptoms associated with opioid withdrawal. Masimo’s measurement technologies are available on many types of devices, from bedside hospital monitors like the Root</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patient Monitoring and Connectivity Hub, to various handheld and portable devices, and to the tetherless Masimo SafetyNet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> remote patient surveillance solution. The Masimo Hospital Automation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Platform facilitates data integration, connectivity, and interoperability through solutions like Patient SafetyNet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Replica</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and UniView</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to facilitate more efficient clinical workflows and to help clinicians provide the best possible care, both in-person and remotely. Leveraging the Company’s expertise in hospital-grade technologies, the Company has also expanded its suite of products intended for use outside the hospital to products for consumers, including Sleep</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a sleep quality solution and the Radius Tº</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> wireless, wearable continuous thermometer.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The use of the trademark Patient SafetyNet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is under license from the University HealthSystem Consortium.</span></div>
us-gaap Fiscal Period
FiscalPeriod
<div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiscal Periods</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows a conventional 52/53 week fiscal year. Under a conventional 52/53 week fiscal year, a 52 week fiscal year includes four quarters of 13 weeks while a 53 week fiscal year includes three 13 week fiscal quarters and one 14 week fiscal quarter. The Company’s last 53 week fiscal year was fiscal year 2020. Fiscal year 2021 is a 52 week fiscal year ending January 1, 2022. All references to years in these notes to condensed consolidated financial statements are fiscal years unless otherwise noted.</span></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation.</span></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of standalone selling prices, variable consideration, total consideration allocated to each performance obligation within a contract, inventory valuation, valuation of the Company’s equity awards, valuation of identifiable assets and liabilities connected with business combinations, deferred taxes and any associated valuation allowances, deferred revenue, uncertain income tax positions, and litigation costs and related accruals. Actual results could differ from such estimates.</span></div>
masi Numberof Sourcesof Product Revenue
NumberofSourcesofProductRevenue
4 segment
CY2021Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2740000 USD
CY2019Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
3395000 USD
us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
3442000 USD
us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
428000 USD
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
-2347000 USD
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
-97000 USD
us-gaap Product Warranty Expense
ProductWarrantyExpense
891000 USD
us-gaap Product Warranty Expense
ProductWarrantyExpense
883000 USD
CY2021Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2944000 USD
CY2020Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2843000 USD
CY2021Q4 us-gaap Profit Loss
ProfitLoss
57771000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
49405000 USD
us-gaap Profit Loss
ProfitLoss
161389000 USD
us-gaap Profit Loss
ProfitLoss
169633000 USD
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55143000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54997000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55125000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54543000 shares
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.05
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.90
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.11
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55143000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54997000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55125000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54543000 shares
CY2021Q4 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2521000 shares
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3283000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2526000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3490000 shares
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57664000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58280000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57651000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58033000 shares
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.00
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.92
CY2021Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
300000 shares
us-gaap Interest Paid Net
InterestPaidNet
202000 USD
us-gaap Interest Paid Net
InterestPaidNet
194000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
36898000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
35961000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
5567000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
4699000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4917000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
9900000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3182000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3988000 USD
masi Settlementofpromissorynoteinconnectionwithacquisitionoptionexercise
Settlementofpromissorynoteinconnectionwithacquisitionoptionexercise
0 USD
masi Settlementofpromissorynoteinconnectionwithacquisitionoptionexercise
Settlementofpromissorynoteinconnectionwithacquisitionoptionexercise
5100000 USD
us-gaap Other Significant Noncash Transaction Consideration Given
OtherSignificantNoncashTransactionConsiderationGiven
3,400
us-gaap Payments To Acquire Additional Interest In Subsidiaries
PaymentsToAcquireAdditionalInterestInSubsidiaries
3374000 USD
us-gaap Payments To Acquire Additional Interest In Subsidiaries
PaymentsToAcquireAdditionalInterestInSubsidiaries
0 USD
masi Proceedsfromstockoptionsexercisedunsettledatperiodend
Proceedsfromstockoptionsexercisedunsettledatperiodend
112000 USD
masi Proceedsfromstockoptionsexercisedunsettledatperiodend
Proceedsfromstockoptionsexercisedunsettledatperiodend
27000 USD
masi Fairvalueofcommonstockreceivedforpaymentofstockoptionexerciseprice
Fairvalueofcommonstockreceivedforpaymentofstockoptionexerciseprice
0 USD
masi Fairvalueofcommonstockreceivedforpaymentofstockoptionexerciseprice
Fairvalueofcommonstockreceivedforpaymentofstockoptionexerciseprice
220000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
652354000 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
669056000 USD
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1581000 USD
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
3384000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
653935000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
672440000 USD
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
121593000 USD
CY2021Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
133098000 USD
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
14383000 USD
CY2021Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
15985000 USD
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
66352000 USD
CY2021Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
66869000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
202328000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
215952000 USD
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
30351000 USD
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
30235000 USD
CY2021Q4 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
26685000 USD
CY2021Q1 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
23206000 USD
CY2021Q4 us-gaap Prepaid Taxes
PrepaidTaxes
15501000 USD
CY2021Q1 us-gaap Prepaid Taxes
PrepaidTaxes
14782000 USD
CY2021Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
10715000 USD
CY2021Q1 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
14545000 USD
CY2021Q4 us-gaap Prepaid Royalties
PrepaidRoyalties
3066000 USD
CY2021Q1 us-gaap Prepaid Royalties
PrepaidRoyalties
3081000 USD
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1496000 USD
CY2021Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
3397000 USD
CY2021Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
1359000 USD
CY2021Q1 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
2283000 USD
CY2021Q4 us-gaap Deposit Assets
DepositAssets
0 USD
CY2021Q1 us-gaap Deposit Assets
DepositAssets
3374000 USD
CY2021Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
2599000 USD
us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
40000000 USD
CY2021Q1 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
7513000 USD
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
91772000 USD
CY2021Q1 us-gaap Other Assets Current
OtherAssetsCurrent
102416000 USD
CY2021Q4 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
12000000 USD
CY2020Q3 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
13000000 USD
us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
31000000 USD
CY2021Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
93879000 USD
CY2021Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
81074000 USD
CY2021Q4 masi Salestypelease Allowancefor Credit Loss
SalestypeleaseAllowanceforCreditLoss
239000 USD
CY2021Q1 masi Salestypelease Allowancefor Credit Loss
SalestypeleaseAllowanceforCreditLoss
202000 USD
CY2021Q4 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
93640000 USD
CY2021Q1 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
80872000 USD
CY2021Q4 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
26685000 USD
CY2021Q1 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
23206000 USD
CY2021Q4 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
66955000 USD
CY2021Q1 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
57666000 USD
CY2021Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths
6888000 USD
CY2021Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears
25995000 USD
CY2021Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears
21371000 USD
CY2021Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Four Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears
17349000 USD
CY2021Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Five Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears
11535000 USD
CY2021Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Thereafter
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter
10502000 USD
CY2021Q4 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
93640000 USD
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
134136000 USD
CY2021Q4 masi Deferred Sales Commissions
DeferredSalesCommissions
9976000 USD
CY2021Q1 masi Deferred Sales Commissions
DeferredSalesCommissions
7477000 USD
CY2021Q4 masi Prepaid Discount
PrepaidDiscount
6820000 USD
CY2021Q1 masi Prepaid Discount
PrepaidDiscount
7336000 USD
CY2021Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
4317000 USD
CY2021Q1 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
3925000 USD
CY2021Q4 masi Equipmentleasedtocustomers
Equipmentleasedtocustomers
1486000 USD
CY2021Q1 masi Equipmentleasedtocustomers
Equipmentleasedtocustomers
1338000 USD
CY2021Q4 us-gaap Deferred Costs And Other Assets
DeferredCostsAndOtherAssets
22599000 USD
CY2021Q1 us-gaap Deferred Costs And Other Assets
DeferredCostsAndOtherAssets
20076000 USD
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
426081000 USD
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
406647000 USD
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
151152000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
274929000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
272511000 USD
CY2021Q4 us-gaap Depreciation
Depreciation
6500000 USD
CY2020Q3 us-gaap Depreciation
Depreciation
5800000 USD
us-gaap Depreciation
Depreciation
18800000 USD
us-gaap Depreciation
Depreciation
16000000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
117676000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
110589000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
43587000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
36666000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
74089000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
73923000 USD
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P12Y
CY2021Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2700000 USD
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1600000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7600000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5200000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
9211000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
8377000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
7964000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
7352000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
6274000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
34911000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
74089000 USD
CY2021Q1 us-gaap Goodwill
Goodwill
103206000 USD
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-1964000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
101242000 USD
CY2021Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.026
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
31561000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32324000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6147000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5975000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27471000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28373000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
33618000 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
34348000 USD
CY2021Q4 masi Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
13000000 USD
CY2021Q1 masi Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
9200000 USD
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1509000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7093000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6649000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5123000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3998000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
12317000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
36689000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3071000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
33618000 USD
CY2021Q4 us-gaap Operating Lease Cost
OperatingLeaseCost
2100000 USD
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1800000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
6200000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
5200000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
31561000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32324000 USD
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
13928000 USD
CY2021Q1 us-gaap Equity Method Investments
EquityMethodInvestments
8002000 USD
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
4397000 USD
CY2021Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
4316000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
49886000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
44642000 USD
CY2021Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2021Q1 us-gaap Deferred Revenue
DeferredRevenue
33221000 USD
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
34392000 USD
CY2021Q1 us-gaap Deferred Revenue
DeferredRevenue
33221000 USD
CY2021Q4 masi Accruedrebatesandallowances
Accruedrebatesandallowances
11322000 USD
CY2021Q1 masi Accruedrebatesandallowances
Accruedrebatesandallowances
12127000 USD
CY2021Q4 us-gaap Accounts Payable Other Current And Noncurrent
AccountsPayableOtherCurrentAndNoncurrent
4744000 USD
CY2021Q1 us-gaap Accounts Payable Other Current And Noncurrent
AccountsPayableOtherCurrentAndNoncurrent
3829000 USD
CY2021Q4 us-gaap Other Liabilities And Deferred Revenue Noncurrent
OtherLiabilitiesAndDeferredRevenueNoncurrent
50458000 USD
CY2021Q1 us-gaap Other Liabilities And Deferred Revenue Noncurrent
OtherLiabilitiesAndDeferredRevenueNoncurrent
49177000 USD
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3817000 USD
CY2021Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4242000 USD
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
46641000 USD
CY2021Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
44935000 USD
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
23425000 USD
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
22254000 USD
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
34392000 USD
CY2021Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
987300000 USD
CY2021Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2021Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
272700000 USD
CY2021Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
12081000 USD
CY2021Q1 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
14365000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12046000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6794000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6147000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5975000 USD
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4443000 USD
CY2021Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
5910000 USD
CY2021Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
3947000 USD
CY2021Q1 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
4058000 USD
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
3446000 USD
CY2021Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
3655000 USD
CY2021Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
2944000 USD
CY2021Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
2740000 USD
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
1686000 USD
CY2021Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
1682000 USD
CY2021Q4 masi Accrued Donations Current
AccruedDonationsCurrent
1307000 USD
CY2021Q1 masi Accrued Donations Current
AccruedDonationsCurrent
495000 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3071000 USD
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4096000 USD
CY2021Q4 masi Minority Interest Current Liabilities
MinorityInterestCurrentLiabilities
0 USD
CY2021Q1 masi Minority Interest Current Liabilities
MinorityInterestCurrentLiabilities
3469000 USD
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
51118000 USD
CY2021Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
53239000 USD
CY2021Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
2400000 USD
CY2021Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1700000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27471000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28373000 USD
CY2021Q4 masi Income Tax Payable Noncurrent
IncomeTaxPayableNoncurrent
16980000 USD
CY2021Q1 masi Income Tax Payable Noncurrent
IncomeTaxPayableNoncurrent
19245000 USD
CY2021Q4 masi Unrecognized Tax Benefits Liabilities Noncurrent
UnrecognizedTaxBenefitsLiabilitiesNoncurrent
15352000 USD
CY2021Q1 masi Unrecognized Tax Benefits Liabilities Noncurrent
UnrecognizedTaxBenefitsLiabilitiesNoncurrent
11777000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
6063000 USD
CY2021Q1 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
6247000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4511000 USD
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5434000 USD
CY2021Q4 us-gaap Deferred Credits And Other Liabilities
DeferredCreditsAndOtherLiabilities
70377000 USD
CY2021Q1 us-gaap Deferred Credits And Other Liabilities
DeferredCreditsAndOtherLiabilities
71076000 USD
CY2021Q4 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
0 shares
CY2020Q3 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
0 shares
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
547000 shares
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
4000 shares
CY2021Q4 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
0
CY2020Q3 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
0
us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
235.88
us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
164.44
CY2021Q4 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
0 USD
CY2020Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
0 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
128917000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
591000 USD
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
12600000 USD
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
11900000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
33500000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
36400000 USD
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10700000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4400000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3448000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
77.44
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3105000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
80.55
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2255000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
85000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
250.15
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
150000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
146.62
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
278000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
57.88
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
55.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
three years
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.002
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.003
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.003
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.009
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.002
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.017
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y1M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.327
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.336
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.309
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.347
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.269
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.355
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
66.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
75.72
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
50.39
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
589600000 USD
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
484500000 USD
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
35400000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
56900000 USD
CY2021Q4 us-gaap Interest Income Other
InterestIncomeOther
242000 USD
CY2020Q3 us-gaap Interest Income Other
InterestIncomeOther
797000 USD
us-gaap Interest Income Other
InterestIncomeOther
677000 USD
us-gaap Interest Income Other
InterestIncomeOther
5120000 USD
CY2021Q4 us-gaap Interest Expense
InterestExpense
87000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
84000 USD
us-gaap Interest Expense
InterestExpense
259000 USD
us-gaap Interest Expense
InterestExpense
250000 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
21600000 USD
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
647000 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1153000 USD
CY2021Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-233000 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1246000 USD
CY2021Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000 USD
CY2021Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-78000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1357000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-735000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6108000 USD
CY2021Q4 us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
6400000 USD
CY2020Q3 us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
3100000 USD
us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
12000000 USD
us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
20200000 USD
masi Percentage Of Revenue One Customer
PercentageOfRevenueOneCustomer
0.112
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
19600000 USD
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.03
CY2021Q4 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
900000 USD
CY2020Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
800000 USD
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
2800000 USD
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
2400000 USD
CY2021Q4 masi Severance Plan Participation Agreements
SeverancePlanParticipationAgreements
5 Agreement
masi Supplemental Unemployment Benefits Severance Benefits Required Noticeof Resignation
SupplementalUnemploymentBenefitsSeveranceBenefitsRequiredNoticeofResignation
P6M
CY2021Q4 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
155900000 USD
CY2021Q4 us-gaap Other Commitment
OtherCommitment
3400000 USD
CY2021Q4 masi Bank Balances
BankBalances
652400000 USD
CY2021Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
5000000 USD
CY2021Q4 masi Percentage Of Revenue One Customer
PercentageOfRevenueOneCustomer
0.150
CY2021Q4 masi Percentage Of Revenue Two Customer
PercentageOfRevenueTwoCustomer
0.104
CY2020Q3 masi Percentage Of Revenue One Customer
PercentageOfRevenueOneCustomer
0.110
CY2020Q3 masi Percentage Of Revenue Two Customer
PercentageOfRevenueTwoCustomer
0.093
masi Percentage Of Revenue One Customer
PercentageOfRevenueOneCustomer
0.146
masi Percentage Of Revenue Two Customer
PercentageOfRevenueTwoCustomer
0.104
masi Percentage Of Revenue Two Customer
PercentageOfRevenueTwoCustomer
0.100
CY2021Q1 us-gaap Noncurrent Assets
NoncurrentAssets
273849000 USD
CY2021Q4 masi Concentration Risk Ar Customer
ConcentrationRiskARCustomer
1 Customer
CY2021Q4 masi Concentration Risk Longlived Asset Geographic Area Percentage
ConcentrationRiskLonglivedAssetGeographicAreaPercentage
1.000
CY2019Q3 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
10500000 USD
CY2021Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
307413000 USD
CY2021Q4 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1.000
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
278112000 USD
CY2020Q3 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1.000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
911574000 USD
us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1.000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
848690000 USD
us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1.000
CY2021Q4 us-gaap Noncurrent Assets
NoncurrentAssets
276415000 USD
CY2021Q1 masi Concentration Risk Longlived Asset Geographic Area Percentage
ConcentrationRiskLonglivedAssetGeographicAreaPercentage
1.000

Files In Submission

Name View Source Status
0000937556-21-000124-index-headers.html Edgar Link pending
0000937556-21-000124-index.html Edgar Link pending
0000937556-21-000124.txt Edgar Link pending
0000937556-21-000124-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
masi-20211002.htm Edgar Link pending
masi-20211002.xsd Edgar Link pending
masi-20211002x10qex311.htm Edgar Link pending
masi-20211002x10qex312.htm Edgar Link pending
masi-20211002x10qex321.htm Edgar Link pending
masi-20211002_cal.xml Edgar Link unprocessable
masi-20211002_def.xml Edgar Link unprocessable
masi-20211002_g1.jpg Edgar Link pending
masi-20211002_htm.xml Edgar Link completed
masi-20211002_lab.xml Edgar Link unprocessable
masi-20211002_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending